Moore Lauren M, Wilkinson Rachel, Altan Mehmet, Toki Maria, Carvajal-Hausdorf Daniel E, McGuire John, Ehrlich Barbara E, Rimm David L
1Department of Pathology, Yale School of Medicine, New Haven, CT USA.
3Department of Thoracic/ Head & Neck Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX USA.
NPJ Breast Cancer. 2018 Mar 12;4:6. doi: 10.1038/s41523-018-0057-7. eCollection 2018.
Neuronal calcium sensor-1 (NCS-1) has been identified as a binding partner of the taxane, paclitaxel. Our previous study showed that overexpression of NCS-1 increased the efficacy of paclitaxel in vitro, but was associated with poor clinical outcome. Here, we determine if NCS-1 expression is associated with pathological complete response (pCR) to taxane-based neoadjuvant chemotherapy in 105 pre-treatment breast cancer biopsies. Elevated expression of NCS-1 was found to be positively associated with pCR. These results suggest that NCS-1 may be a predictive biomarker for response to taxane-based neoadjuvant chemotherapy in breast cancer.
神经元钙传感器-1（NCS-1）已被确定为紫杉烷类药物紫杉醇的结合伴侣。我们之前的研究表明，NCS-1的过表达在体外可提高紫杉醇的疗效，但与不良临床结果相关。在此，我们在105份乳腺癌治疗前活检样本中确定NCS-1表达是否与基于紫杉烷的新辅助化疗的病理完全缓解（pCR）相关。结果发现，NCS-1的高表达与pCR呈正相关。这些结果表明，NCS-1可能是乳腺癌中基于紫杉烷的新辅助化疗反应的预测生物标志物。
